



Corporate Presentation

July/2021

New growth cycle and value innovation

















Index

- 1 About Odontoprev
- 2 Dental benefits: an incipient sector in Brazil
- 3 Inside OdontoPrev: strategic competitive advantages
- 4 Financial and Operational Performance
- 5 Capital Markets



About **Odontoprev**

About Odontoprev

Odontoprev, listed in São Paulo since 2006, is the leading dental benefits provider in Latin America with more than 7.5 million members. The company is a member of the Novo Mercado at B3, a constituent of the FTSE4Good Index and one of 9 brazilian companies included in the Bloomberg 2021 Gender -Equality Index (GEI).

Largest dental benefits company in Latin America, over 7.5 million clients;

- Asset-light business model, with proprietary dental IT platform and exclusive distribution channels;
- Zero debt, negative working capital needs, low capex requirements, quarterly dividends, high payout practice;
- Chairman # CEO since 1998, professional management team since foundation, 1 share = 1 vote, 100% tag-along rights.

Net revenues, adjusted EBITDA and net income evolution since IPO 2006 to APR20-MAR21 CAGR



Dental **benefits**

an incipiente sector in Brazil

Brazil leads the global ranking of dentists

Number of dentists per country (thousand)



Source: FDI World Dental Federation – The Oral Health Atlas 2009, Federal Council of Dentistry– Brazil (November 2020) and Eurostat 2015-2016

Medical and dental plans membership growth

Million members



Top dental care players, by annual revenues and number of beneficiaries





Source: Odontoprev and ANS

11

APR20-MAR21 Dental players net revenue and average ticket R\$ million

Average Ticket (R\$ / member / month)



12

(R\$ million)

Leadership position on each and every region

Key dental players per region (thousand members)

| | 💙 odontoprev | | SulAmérica | | Interodonto | | hapvida +odonto | | amil | | MetLife | | PORTO SEGURO Odontologico | |
|--------------------|--------------|---------|------------|---------|-------------|---------|--------------------|---------|---------|---------|---------|---------|---------------------------------|---------|
| | Members | Ranking | Members | Ranking | Members | Ranking | Members | Ranking | Members | Ranking | Members | Ranking | Members | Ranking |
| Southeast | 4,334 | 1st | 1,928 | 3rd | 2,691 | 2nd | 545 | 7th | 1,624 | 4th | 825 | 5th | 596 | 6th |
| South | 728 | 1st | 278 | 3rd | 75 | 10th | 81 | 9th | 120 | 4th | 105 | 5th | 16 | 20th |
| Middle- West | 549 | lst | 182 | 3rd | 33 | 11th | 202 | 2nd | 146 | 4th | 109 | 6th | 35 | 10th |
| North Northeast | 1,915 | 1st | 488 | 3rd | 45 | 21th | 1,870 | 2nd | 258 | 4th | 106 | 8th | 46 | 20th |
| Total ¹ | 7,529 | 1st | 2,880 | 2nd | 2,844 | 3rd | 2,698 | 4th | 2,151 | 5th | 1,145 | 6th | 693 | 8th |

Source: ANS May/21

13 1- Considers unidentified beneficiaries

Key metrics of peer companies, APR20-MAR21



Odontoprev competitive advantages X Peers





Rational pricing + value innovation = higher ticket

R\$/member/month Average ticket evolution: 2015 – 1Q21





Source: Odontoprev

APR20-MAR21 Medical players net revenue and average ticket

R\$ million

Average Ticket (R\$ / member / month)



Strategic competitive advantages

Attractive cost dynamics

 \heartsuit

Over time, Odontoprev dental plans present a price and cost profile...



Short-term contract: 1 year tenor



- Predictable cost evolution due to prevention
- Long-term contract: 2 year + duration

²⁰ ...predictable and more attractive than medical plans.

Proprietary dental IT Platform allows high quality standards





Complete electronic record of all beneficiaries

✓ 3 decades of actuarial data

Risk management and fraud prevention

Largest and best dentist network

31,000 dentists at 2,700 cities

National distribution

- Differentiated academic background
 - Continuous education



Financial and Operational performance

Revenue, EBITDA and Net Income evolution

 \heartsuit

R\$ million e %Sales





25

MAR21

Revenues per segment

R\$ million



¹includes sales of services and products

Revenues and average ticket evolution per segment since 2014

R\$ million



Revenues and average ticket per segment

APR20-MAR21 x 2014





Two business segments

 \heartsuit

GDP impact Penetration **Growth Potential Own distribution** 1Q21 Average ticket (R\$/member/month) **Barriers to entry**





Quarterly Net Additions

Thousand members



1Q21 Net Additions

Thousand members

 \heartsuit



SME - Revenue growth

R\$ million



Individual Plans - Revenue growth

 \heartsuit





MAR21

Bank channels generate higher sales price and lower acquisition cost in Individual Plans



BRASILDENTAL EBITDA and Net Income evolution

 \heartsuit

R\$ million and % of Sales


Quarterly and LTM Cost of Services

% Sales



— Quarterly – – LTM

Cost of Services per segment (% Sales)



Selling expenses per segment

% of Sales LTM





% of Sales



Net Revenue and Contribution Margin growth - Corporate



Net Revenue and Contribution Margin growth - SME



Net Revenue and Contribution Margin growth – Individual Plans







G&A: APR20-MAR21 x APR19-MAR20

Allowance for doubtful receivables

 \heartsuit

R\$ million and % of Sales



Adjusted EBITDA: 1Q21 x 1Q20

R\$ million % of Sales



Adjusted EBITDA: APR20-MAR21 x APR19-MAR20

R\$ million % of Sales



Dental care ratio and Adjusted EBITDA margin since the IPO

% of Sales



Adjusted EBITDA since the IPO

R\$ million and % of Sales



33.6%

MAR21

Adjusted EBITDA margin

Adjusted EBITDA and CAPEX



MAR21





Net Income and net margin since the IPO

 \heartsuit



22.4%



----- Net margin

Net Cash evolution

R\$ million



 \heartsuit

Net cash and excess solvency level (R\$ million)



In 2Q20, the Company adhered to RN 451 of the National Health Agency (ANS), setting the required solvency at 75%, increasing the potential for distribution of future dividends



Cash flow: 1Q21





Cash flow since IPO: dividends our #1 priority

R\$ million

Since the IPO in 2006, Odontoprev business model required CAPEX of R\$200 million, compared to cash generation of R\$3.5 billion In the period, cash dividends was R\$2.6 billion.



Capital Markets

Odontoprev total shareholder return since IPO x IBrX 980% 💙 odontoprev 880% +15% p.y. 780% 680% 580% 480% **IBrX** Munim 380% +10% p.y. 280% 180% 80% -20% 2007 2021 2006 2008 2009 2010 2011 2012 2013 2014 2015 2016 2017 2018 2019 2020 -5.4% ODPV3: +30.8% -46.0% +182.6% +80.4% +8.0% +25.4% -5.2% +4.5% +26.1% -10.8% +22.1% +0.1% +37.1% +30.4% - 12.5% +10.3% **IBX:** +6.9% +47.8% -41.8% +72.8% +2.6% -11.4% +11.5% -3.1% -2.8% -12.4% +27.5% +15.4% +33.4% +3.5% +36.7%

Increasing number of individual investors



Global shareholder structure: investors from more than 30 countries



Professional management team since foundation in the 80's



Key metrics for management's compensation



ESG metrics

Since the beginning of the pandemic, more than 6,000 Personal Protective Equipment (PPE's) were delivered to selected accredited dentists.

| Environmental key indicators | 1Q20 | 1Q21 | |
|--|---------|---------|--|
| Total consumption of electricity (kWh) [GRI-302] | 235,613 | 196,925 | |
| Total consumption of water (m ³) [GRI-303] | 1,906 | 1,220 | |
| Greenhouse gas emissions per scope (tCO2e) [GRI 305] | 142 | 94 | |
| Waste Management[GRI 306] | 1,948 | 666 | |

| | 1T20 | 1T21 |
|------------------------------|-------|-------|
| Total employees ¹ | 2,133 | 1,912 |
| Call Center employees | 570 | 501 |

| Total turnover | 5.9% | 6.0% |
|--------------------------------------|-------|-------|
| [GRI G4-LA12] Gender distribution | | |
| % Men | 26.1% | 25.6% |
| % Women | 73.9% | 74.4% |

| % Women at Strategic Management | 46.0% | 44.3% |
|---------------------------------|-------|-------|
|---------------------------------|-------|-------|

Odontoprev as a member of International ESG Indexes





Odontoprev was confirmed as a FTSE4Good Index Series constituent, for the fourth consecutive year.

Odontoprev was included in the **Bloomberg 2020 Gender-Equality Index (GEI)** for the second time. Award winning IR Team



Institutional Investor

<u>Awarded by the Latin America Executive Team / Healthcare</u> 2010 / 2011 / 2012 / 2013 / 2014 / 2015 / 2016 / 2017 / 2018 / 2019 / 2020

... Thank you very much!

Why Odontoprev?



| UPCOMING EVENTS | | | | | | | | | |
|----------------------|--------------------|--|--|--|--|--|--|--|--|
| Date | Broker | Event | | | | | | | |
| Jun 22-23, 2021 | UBS > BB | LatAm Conference | | | | | | | |
| Jul 28, 2021 | | 2Q21 Earnings Release | | | | | | | |
| Jul 29, 2021 | | 2Q21 Webcast | | | | | | | |
| Aug 23-27, 2021 | ð Santander | 22 nd Santander Annual Conference | | | | | | | |
| Sep 13-16, 2021 | Morgan Stanley | 24 th Annual Latin America Conference | | | | | | | |
| Oct 27, 2021 | | 3Q21 Earnings Release | | | | | | | |
| Oct 28, 2021 | | 3Q21 Webcast | | | | | | | |
| Nov 30 - Dec 2, 2021 | UBS >> BB | Global Emerging Markets One-on-One Conference | | | | | | | |

Contact Investor Relations



Appendix

| R\$ million | 2006 | 2007 | 2008 | 2009 | 2010 | 2011 | 2012 | 2013 | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | APR20 MAR21 | CAGR |
|------------------------------------|-------|-------|-------|-------|-------|-------|-------|-------|-------|-------|-------|-------|-------|-------|-------|----------------|------|
| Net Revenues | 182 | 259 | 318 | 382 | 685 | 835 | 955 | 1,070 | 1,156 | 1,250 | 1,365 | 1,437 | 1,592 | 1,795 | 1,765 | 1,762 | 17% |
| Average ticket (R\$/memeber/month) | 12.25 | 12.53 | 12.07 | 12.80 | 12.87 | 13.66 | 14.33 | 15.22 | 16.07 | 17.04 | 18.58 | 19.66 | 20.43 | 21.13 | 20.47 | 20.30 | 4% |
| Number of members (000) | 1,492 | 2,113 | 2,460 | 4,175 | 4,978 | 5,533 | 5,976 | 6,172 | 6,316 | 6,409 | 6,267 | 6,309 | 7,230 | 7,400 | 7,510 | 7,544 | 12% |
| EBITDA | 46 | 60 | 76 | 81 | 154 | 208 | 227 | 273 | 305 | 327 | 300 | 352 | 415 | 418 | 544 | 591 | 20% |
| EBITDA Margin (%) | 25.1 | 23.3 | 23.9 | 21.1 | 22.4 | 24.9 | 23.8 | 25.5 | 26.4 | 26.2 | 22.0 | 24.5 | 26.1 | 23.3 | 30.8 | 33.6 | 25.2 |
| Net Income | 17 | 48 | 55 | 59 | 121 | 145 | 146 | 188 | 195 | 221 | 216 | 245 | 285 | 285 | 361 | 395 | 25% |
| Market Cap | 872 | 1,122 | 587 | 2,833 | 4,443 | 4,711 | 5,701 | 5,223 | 5,239 | 5,021 | 6,694 | 8,453 | 7,305 | 8,963 | 7,730 | 6,987 | 16% |
| ODPV3 Return (%) | 22 | 31 | -46 | 183 | 80 | 8 | 25 | -5 | 5 | 0 | 37 | 30 | -13 | 26 | -14 | -9 | 15% |
| IBX-100 (%) | 7 | 48 | -42 | 73 | 3 | -11 | 12 | -3 | -3 | -12 | 37 | 28 | 15 | 33 | 4 | 62 | 10% |

